Rankings
▼
Calendar
IRWD Q3 2025 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
IRWD
Ironwood Pharmaceuticals, Inc.
$629M
Q3 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$122M
+33.3% YoY
Gross Profit
$122M
100.0% margin
Operating Income
$75M
61.8% margin
Net Income
$40M
32.8% margin
EPS (Diluted)
$0.23
QoQ Revenue Growth
+43.2%
Cash Flow
Operating Cash Flow
$48M
Free Cash Flow
$48M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$396M
Total Liabilities
$660M
Stockholders' Equity
-$264M
Cash & Equivalents
$140M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$122M
$92M
+33.3%
Gross Profit
$122M
$62M
+97.6%
Operating Income
$75M
$26M
+194.4%
Net Income
$40M
$4M
+999.3%
Revenue Segments
Royalty
$900,000
64%
Collaborative arrangement, collaboration and license agreements
$423,000
30%
Collaborative arrangement, other agreements
$87,000
6%
Geographic Segments
North America
$120M
99%
Europe and Other
$944,000
1%
← FY 2025
All Quarters
Q4 2025 →